Drug Profile
Denosumab biosimilar - Luye Pharma
Alternative Names: Anti-RANKL monoclonal antibody; BA-1102; BA-6101; Boluojia; Boyoubei; LY-01011; LY-06006Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Shandong Boan Biotechnology
- Developer Luye Pharma Group; Parexel International; Shandong Boan Biotechnology
- Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoporosis
- Preregistration Bone metastases; Multiple myeloma
- Phase III Postmenopausal osteoporosis
- Phase I Unspecified
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Bone metastases in Europe (SC, Injection)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Bone metastases in USA (SC, Injection)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Multiple-myeloma in Europe (SC, Injection)